Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

AnHeart’s investigational medicine taletrectinib shrank tumors in more than 90% of people with ROS1+ NSCLC who were ROS1 TKI naïve in TRUST-II trial ...

ROS1 is a gene which can join (or fuse) with part of another gene. The fusion activates the ROS1 gene in a way that causes uncontrolled cancer cell growth. The gene change is called ROS1 fusion.

(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive pivotal data for ...

Get the latest Nuvalent, Inc. (NUVL) stock news and headlines to help you in your trading and investing decisions.

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities analyst Silvan Tuerkcan maintained a “Market Outperform” rating on Nuvation’s ...

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 Published. Jul 16, 2024 6:30am EDT.

ROS1 rearranged or ROS1-positive non-small cell lung cancer is a subtype of lung cancer that is — makes up about 1 to 2% of non-small cell lung cancer. And it's a … really interesting subtype, because ...

Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib.A third ROS1 TKI approved in 2023 ...

In ROS1-positive NSCLC patients, the drug achieved a 79% ORR in patients who had never previously been treated with a ROS1-targeting TKI, made up of 6% complete responses and 73% partial responses ...